Full-Time

Senior Manager

Regulatory Affairs

Posted on 8/8/2025

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

No salary listed

Bengaluru, Karnataka, India

In Person

Category
Legal & Compliance (2)
,
Required Skills
Marketing
Requirements
  • Experience in New drug registration in India, Clinical trials.
  • Result oriented, ability to work in a fast-paced and evolving environment.
  • Excellent communication and interpersonal negation skills.
  • Strong functional and technical skills related to various dimensions of the regulatory affairs function.
  • Strong project management and commercial skills.
  • Regulatory agency interaction experience is advantage.
  • Good track record on collaboration with Cross functional team.
  • Strong interpersonal skills and proven track record in working effectively with cross functional teams.
  • Having domain knowledge related to subregion country regulation is advantage.
  • Ability to resolve the problem when it arises.
Responsibilities
  • Regulatory Affairs Support: Developing the regulatory strategy including Filling readiness of NDA’s & sNDA.
  • Regulatory Affairs Support: Responsible for ongoing renewals, variations and maintenance of registered products and CDx (devices).
  • Regulatory Affairs Support: Collaborating with global teams during early stage of product development and share the inputs on regulatory requirements from development and data perspective.
  • Regulatory Affairs Support: Understand timelines of the availability of various documents for filling application and supply chain of the new product for which regulatory strategy is been created.
  • Regulatory Affairs Support: Understand likely queries and keep documents ready in advance to either share the same to prevent the query or to have short lead time in submitting query response.
  • Regulatory Affairs Support: Maintain an awareness of country’s regulatory legislation.
  • Regulatory Affairs Support: Monitor progress of marketing applications through the regulatory system.
  • Regulatory Affairs Support: Liaise and negotiate with the relevant authorities to facilitate and secure expeditious regulatory approvals.
  • Regulatory Affairs Support: Monitor SEC recommendation and CTRI on Reg Intel information on the registration.
  • Regulatory Affairs Support: Contribute in Regulatory Policy related matters by providing inputs for draft guidelines / Regulations.
  • Business Support: Responsible independently new product regulatory strategy discussion with area regulatory, responsible collaboration with commercial team for launch plan, managing product lifecycle maintenance activities viz variation submissions, labelling updates, renewals, testing of samples as per stipulated timelines and in line with company and Health Authority set standards for the assigned countries.
  • Business Support: Working with NPI team for product launch plan and establishing country specific artwork.
  • Business Support: Develop and implement regulatory strategies, identify potential regulatory risks and develop mitigation strategies, ensure compliance with labeling, advertising, and promotional regulations, Review and approve labeling, advertising, and promotional materials to ensure compliance with local regulations and guidelines, Collaborate with marketing and sales teams to ensure accurate and compliant communication of product information.
  • Business Support: Stay updated with any changes in labeling, advertising, and promotional regulations and provide necessary guidance and training to relevant teams.
  • Business Support: Provide regulatory input on marketing campaigns and strategies to ensure accurate and compliant product claims.
  • Business Support: Attend ARPT /GRPT and Keep up to date for product registration, variation, line extension and other related law & regulations knowledge.
  • Business Support: Monitor and disseminate information on changes related to the Regulatory Authority Department: law & regulations affecting registration, manufacture, distribution and sale & marketing of AbbVie products.
  • Business Support: Facilitate communication between Area Regulatory lead and the local regulatory authority.
  • Business Support: Monitor the progress of marketing applications and provide updates on registration status during brand team meetings, as applicable.
  • Business Support: Identify potential regulatory hurdles or challenges and work collaboratively to address them.
  • Business Support: Provide regulatory input and support for marketing plans, product launches and other cross- functional activities.
  • Business Support: Review and provide input and approval on promotional materials, product information and labels for regulatory compliance.
  • Business Support: Provide support to Institutional business support as and when required to acquire documents viz. Market Standing Certificate, No Conviction Certificate GMP, Manufacturing License and Proprietary Article Certificate etc.
  • RA Process: Regulatory submissions and approvals in the most efficient and cost-effective manner for assigned products and countries.
  • RA Process: Ensure 100% compliance to internal processes and policies and also Health Authority requirement.
  • RA Compliance: Ensure compliance with local requirements and company policy, such as timely notification to Area of local renewal requirements. Implement remediation plan to address identified gaps.
  • RA Compliance: In collaboration with cross-functional groups, e.g. Legal, Medical, Pharmacovigilance, Quality and supply chain to ensure the compliance with relevant legal/regulatory requirements and reviewing and approving promotional materials as per the approved labels.
  • RA Compliance: Up to date of product registration, variation, line extension and other related law & regulations knowledge.
  • RA Compliance: Review, analyze and co-ordinate data for variations submission to marketed products according to priorities and responses to deficiency letters.
  • RA Compliance: Monitor progress of variations approval process within Regulatory Authority.
  • RA Compliance: Liaise and negotiate with the relevant authorities to facilitate and secure expeditious regulatory approvals.
  • RA Compliance: Manage labeling changes, artwork development and artwork approval of packaging material components.
  • RA Compliance: Update and maintain regulatory databases.
Desired Qualifications
  • Education: Degree in Life Sciences or Biotechnology or Biomedical science equivalent to equivalent to a B. Pharm/M.Pharm/MSc degree
  • Experience: 6-7 years of experience in Regulatory Affairs for India region
  • Regulatory agency interaction experience is advantage
  • Having domain knowledge related to subregion country regulation is advantage

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $15B, up 12.4%, raising FY EPS guidance to $14.08-$14.28.
  • Skyrizi secured Ontario and Alberta listings for ulcerative colitis reimbursement.
  • $1.45B Kestrel deal advances KRAS inhibitor for oncology pipeline expansion.

What critics are saying

  • Oruka's ORKA-001 outperforms Skyrizi in psoriasis trials, eroding $17.6B revenue.
  • FDA rejected trenibotulinumtoxinE over manufacturing, delaying aesthetics launch.
  • ABBV-295 trails Lilly's eloralintide by 2-3 years in $130B obesity market.

What makes AbbVie unique

  • AbbVie spun off from Abbott in 2013, focusing R&D on immunology, oncology, neuroscience.
  • Skyrizi generated $17.6B in 2025, capturing 45% US biologic psoriasis market share.
  • 250+ external innovation partners accelerate AbbVie's transformational medicine pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Company News

AllSci
Apr 13th, 2026
Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m.

Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m. April 13, 2026 A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an agreement announced April 10, 2026. The deal grants AbbVie rights to develop, manufacture, and commercialize the compounds globally, excluding mainland China, Hong Kong, and Macau. The program covers multiple compounds at stages ranging from preclinical to Phase I in China, all targeting pain-related indications. Under the terms, Haisco receives a USD 30 million upfront payment and is eligible for up to USD 715 million in aggregate development, regulatory, and commercial milestones, bringing the total potential deal value to USD 745 million. Haisco is also eligible for tiered royalties on future net sales. Specific milestone triggers and royalty rates were not disclosed. Deal context. The compounds involved are described by Haisco as novel medicines for pain, but the press release does not identify specific molecule names, biological targets, or mechanisms of action. Haisco is known to be pursuing fast-follower NaV1.8 programs - targeting a voltage-gated sodium channel expressed in peripheral sensory neurons that plays a key role in pain signal transmission - following the approval of Vertex Pharmaceuticals' suzetrigine (Journavx) in January 2025. The Chinese firm has secured patents describing VX-548-derived scaffolds incorporating bioisosteric substitutions to modify the core structure. AbbVie has identified neuroscience as a core therapeutic focus alongside its established positions in immunology and oncology. However, the company has had limited recent deal activity specifically in pain, suggesting the Haisco transaction may represent an effort to expand its position in this segment within a broader neuroscience strategy. Other deals of note in the neuroscience space include the USD 8.7 billion acquisition of Cerevel Therapeutics in 2023, focused on later-stage CNS assets for schizophrenia, Parkinson's, and epilepsy. The deal also represents the latest collaboration between AbbVie with China-based partners. In January 2026, AbbVie struck a deal worth in excess of USD 5 billion with Remegen for a PD-1/VEGF bispecific antibody, while two separate partnerships were signed in 2025, with Zelgen Biopharmaceuticals for T-cell engagers, and Simcere Pharma for a trispecific antibody. For Haisco, the deal represents an extension of an international out-licensing strategy the company has pursued since 2015. Other notable partners include US based biotech AirNexis, which signed a deal worth in excess of USD 1 billion in January 2026 for PDE/4 respiratory asset of Haisco, HSK39004 The Chengdu-based company has R&D operations in Shanghai and Silicon Valley and has previously pursued international expansion through out-licensing, co-development, and acquisitions. Previous multinational partners include US biotech AirNexis and Italy's Chiesi Farmaceutici SpA. Your email address will not be published. Required fields are marked *

AInvest
Apr 13th, 2026
Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development.

Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development. Monday, Apr 13, 2026 2:26 am ET 1min read Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop novel medicines for pain treatment globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds at various development stages. Haisco will receive a $30 million upfront payment and up to $715 million in milestone payments, plus royalties on future net sales. The collaboration is expected to generate sustainable value and long-term returns. Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop and commercialize two Nav1.8 inhibitors for pain treatment outside of mainland China, Hong Kong, and Macau. The compounds, HSK55718 and HSK51155, are intended for the development of non-opioid analgesics and are at different stages of clinical development. HSK55718 is in Phase I clinical trials in China as an intravenous therapy, while HSK51155 is in the preclinical stage as an oral formulation according to the announcement. Under the terms of the agreement, Haisco will receive a $30 million upfront payment and is eligible for up to $715 million in milestone payments, in addition to royalties on future net sales. AbbVie will also cover certain research and development costs through the proof-of-concept phase. The deal is expected to support Haisco's global expansion and enhance its long-term profitability. The collaboration aligns with Haisco's strategy to advance its innovative drug portfolio and strengthen its international commercialization efforts. Ask Aime: What are the potential impacts of Haisco's licensing deal with AbbVie on its stock performance? Aime insights. What's the performance trend of major Indian companies listed on US stock exchanges? Between Microsoft and Google, which is better for long-term holding? How to evaluate a company's competitive advantage? How does R&D spending compare among semiconductor leaders over years?

WN.com
Apr 12th, 2026
AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.

AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.

Massachusetts Biotechnology Council
Apr 10th, 2026
March update: Antibody Industry Trends (Q1 2026 insights, trends & analysis).

March update: Antibody Industry Trends (Q1 2026 insights, trends & analysis). Apr 10, 2026 Biointron's Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. Gain exclusive insights into current trends such as: * 3 novel antibody drugs approved for the first time in Q1 2026 * Top 20 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$8.5B * Trends in early developability for antibody discovery * Current research into multiple myeloma treatments * A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q2 2026 Selected report highlights. This quarter, three novel monoclonal antibody drugs have been approved by China. * Libevitug (华优诺): First approved in China on January 23, 2026. It is a human mAb targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), indicated for chronic hepatitis D virus infection in adults with or without compensated cirrhosis. * Retlirafusp Alfa (艾泽利): First approved in China on January 7, 2026. It is a bispecific fusion protein that targets PD-L1 and TGF-beta, indicated for fully validated PD-L1 positive (CPS>=1), locally advanced, unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma. * Amdokitug (益赛拓): First approved in China on February 13, 2026. It is a recombinant humanized anti-IL17A IgG1κ mAb, indicated for adult patients with moderate-to-severe plaque psoriasis (PsO) eligible for systemic therapy or phototherapy. Q1 2026 saw many acquisitions, collaborations, and licensing agreements for bispecific and trispecific antibody drugs. Significant investment has been directed toward startups targeting a diverse range of therapeutic areas, such as central nervous system (CNS) disorders and inflammatory diseases. Top 5 deals by volume: * Feb 9: Innovent Biologics announces strategic collaboration with Eli Lilly and Company to develop new medicines globally in oncology and immunology, in potential $8.5B deal. * Jan 12: AbbVie and RemeGen Biosciences announce licensing agreement to develop a novel PD-1/VEGF bispecific in potential $5.6B deal. * Jan 5: Earendil Labs announces strategic collaboration with Sanofi to discover bispecific antibodies for autoimmune diseases in up to $2.56B deal. * Jan 20: GSK to acquire RAPT Therapeutics for $2.2B, gaining anti-IgE antibody to protect against food allergy reactions. * Mar 23: Gilead Sciences to acquire Ouro Medicines, gaining OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases, in potential $2.18B deal. Early developability in discovery. Monoclonal antibody discovery has shifted toward larger, faster pipelines driven by automation and computational design. As a result, early developability assessment has become a critical layer in candidate selection, helping identify molecular risks related to stability, manufacturability, and formulation before they emerge in later development stages. Developability refers to the set of molecular attributes that influence whether an antibody can be efficiently manufactured, formulated, and advanced through development. These properties, while not directly related to antigen binding, can strongly impact stability, product consistency, and downstream feasibility. By combining multi-parameter profiling, high-throughput screening, and predictive tools, developability assessment enables earlier identification of risks, more efficient candidate prioritization, and improved alignment between discovery and downstream development. Antibody startup launches/companies to watch. Date: March 20, 2026 | Seed Round: €17 million Laigo Bio is advancing targeted protein degradation therapies. Their SureTACs(TM) platform, which uses bispecific antibodies to selectively eliminate disease-causing membrane proteins. By pairing target proteins with E3 ligases, the approach induces precise ubiquitination and lysosomal degradation, enabling dual-targeted removal of pathogenic proteins. They aim to develop therapies in oncology and autoimmune diseases. Date: January 26, 2026 | Seed Round: $13 million Fortitude Biomedicines launched to advance immune cell-targeting biologics and molecular glue payload-enabled ADCs for autoimmune diseases and cancer, combining immune cell-targeting biologics with a proprietary ADC platform. Its GLUE-DAC(TM) technology involves molecular glue-mediated protein degradation, aiming to overcome resistance, expand target scope, and improve therapeutic efficacy. Date: January 8, 2026 | Series B: $125 million Diagonal Therapeutics is developing a novel class of clustering antibodies designed to correct dysregulated receptor signaling at the root of genetic diseases. This approach induces receptor clustering to restore normal signaling pathways. Its lead program, DIAG723, targets impaired ALK1 signaling in conditions such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Date: January 8, 2026 | Series B: $107 million EpiBiologics to advance pipeline of novel bispecific antibodies to selectively degrade extracellular and membrane-bound disease drivers in oncology and immunology. Their modular EpiTAC system enables precise degradation of pathogenic proteins directly at the disease site. They aim to deliver therapies across oncology and immunology, including mutation-agnostic strategies against targets such as EGFR. Multiple myeloma treatments. Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells within the bone marrow, leading to impaired hematopoiesis, bone destruction, and organ dysfunction. The disease is driven by genetic and microenvironmental factors that promote tumor cell survival, immune evasion, and resistance to therapy. Despite advances in treatment, multiple myeloma remains largely incurable, with most patients experiencing cycles of response and relapse that require sequential lines of therapy. According to the National Cancer Institute (NCI), there are an estimated 36,110 new cases of multiple myeloma in 2025. The treatment of multiple myeloma has changed significantly over the past decade. Antibody-based modalities have contributed to improved clinical outcomes in pivotal trials, with multiple major pharma players (e.g., Johnson & Johnson, Bristol Myers Squibb, Pfizer) actively competing in this space. Antibodies to watch in Q2 2026. * Bentracimab by SERB Pharmaceuticals: Fab molecule targeting ticagrelor for cardiovascular / hemostasis indications. Currently under US BLA Priority Review, with a PDUFA of Q1 of 2025. * Veligrotug by Viridian Therapeutics, Inc.: mAb targeting IGF-1R for immune-mediated / inflammatory disorder indications. Currently under US, Europe, and Japan review, with a US PDUFA of June 30, 2026. * Apitegromab by Scholar Rock: mAb targeting myostatin for muscular disorder indications. Currently under review in Europe and US, with an EMA decision expected mid-2026, and a PDUFA of September 2026. * Atacicept by Vera Therapeutics, Inc.: Fusion protein targeting BAFF and APRIL for immune-mediated / inflammatory disorder indications. Currently under US BLA Priority Review, with a PDUFA of July 7, 2026. * Garetosmab by Regeneron: mAb targeting activin A protein for genetic disorder indications. Currently under US BLA Priority Review, with a PDUFA of August 2026.

Yahoo Finance
Apr 8th, 2026
AbbVie's dermatology data for Skyrizi and Rinvoq quietly reinforces immunology-heavy investment story

AbbVie presented extensive dermatology data at the American Academy of Dermatology meeting in late March 2026, showcasing long-term outcomes for Skyrizi and Rinvoq. The company shared 24 abstracts, including Phase 3 results for vitiligo and alopecia areata, where upadacitinib is not yet FDA-approved. The FDA recently updated Skyrizi's US prescribing information to include genital and scalp psoriasis data, extending AbbVie's immunology reach into underserved areas. Whilst the new evidence strengthens the clinical foundation for two key immunology products, it does not fundamentally alter AbbVie's investment narrative, which remains heavily dependent on its immunology franchise. AbbVie's narrative projects $77.7 billion revenue and $22.8 billion earnings by 2029, requiring 8.3% annual revenue growth. Analyst fair value estimates range from $249 to $367 per share.

INACTIVE